KPTI - NASDAQ
Karyopharm Therapeutics Inc.
$9.23
+2.3%Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
At a Glance
Live SnapshotKaryopharm Therapeutics Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Karyopharm Therapeutics Inc. Cash Flow Statement
KPTI • NASDAQ
| Karyopharm Therapeutics Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||
-196M | -76.4M | -143.1M | -165.3M | -124.1M | -196.3M | -199.6M | -178.4M | -129M | -109.6M | -118.2M | -75.8M | -33.9M | -15.9M | -10.3M | |
-114K | 340K | 530K | 621K | 789K | 972K | 974K | 735K | 713K | 717K | 634K | 323K | 144K | 122K | 83K | |
0.0 | 0.0 | 0.0 | 0.0 | 1.5M | 904K | -1.4M | 29K | 0.0 | 0.0 | 1.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
14.1M | 18.4M | 21.7M | 35.4M | 29.8M | 24.4M | 15.3M | 17.3M | 20.4M | 22.3M | 17.1M | 14.2M | 3.8M | 653K | 24K | |
78.5M | -69.5M | -3.3M | -294K | 8.1M | 8.4M | 7.2M | 1.4M | 1.2M | 1.2M | 685K | 52K | 88K | 257K | 0.0 | |
28.3M | -302K | 31.4M | -20M | -23.2M | 1.4M | -13.3M | -169K | 33M | 987K | 4M | 9.7M | -360K | -396K | 1.7M | |
-75.4M | -127.5M | -92.7M | -149.6M | -107.1M | -160.2M | -190.8M | -159.1M | -73.7M | -84.4M | -94M | -51.4M | -30.3M | -15.5M | -8.5M | |
INVESTING ACTIVITIES | |||||||||||||||
(0.0) | -142K | (0.0) | -118K | -5.7M | -145K | -206K | -2.4M | -62K | -70K | -1.4M | -2.8M | -57K | -121K | -376K | |
(0.0) | (0.0) | (0.0) | (104.3M) | (5.5M) | (53.5M) | -78.7M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | -58.8M | -159.2M | -226M | -45.2M | -274.6M | -178.5M | -242.8M | -98.4M | -134.7M | -305.2M | -63.8M | (0.0) | (0.0) | (0.0) | |
43.4M | 154.4M | 167.1M | 121.9M | 192.8M | 221M | 257.1M | 137.5M | 115.5M | 159.4M | 215.9M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -104.3M | -5.5M | -53.5M | 78.7M | -105.3M | 17.2M | 24.7M | -82K | -400K | 0.0 | 0.0 | 0.0 | |
(43.4M) | (95.5M) | (7.9M) | -104.3M | (141.8M) | -53.7M | (78.5M) | -107.7M | (17.1M) | (24.6M) | -90.8M | -67M | -57K | -121K | -376K | |
FINANCING ACTIVITIES | |||||||||||||||
9.5M | 1.5M | 1.1M | 189.8M | 9.9M | 161.8M | 46.2M | 145.7M | 74.9M | 50.6M | 92.1M | 112.8M | 113.2M | 9K | 12K | |
20.5M | 83.3M | 0.0 | 0.0 | 60M | 0.0 | 0.0 | 166.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | -43.1M | 0.0 | 4M | 3.7M | 10.3M | 78.1M | 3.5M | 858K | 591K | 616K | 284K | 341K | 0.0 | 0.0 | |
30M | 41.6M | 1.1M | 193.7M | 73.6M | 172.1M | 124.3M | 316.1M | 75.7M | 51.2M | 92.7M | 113.1M | 185.9M | 9.5M | 12M | |
CASH FLOW SUMMARY | |||||||||||||||
20K | -11K | -34K | -488K | -48K | 268K | 19K | -78K | 200K | -63K | -99K | -8K | 0.0 | 0.0 | 0.0 | |
-1.9M | 9.6M | -83.7M | -60.6M | 108.3M | -41.6M | 12M | 49.3M | 19.3M | -8.7M | -92.3M | -5.4M | 155.6M | -6.1M | 3.1M | |
62.8M | 53.2M | 136.9M | 197.4M | 89.1M | 130.7M | 118.7M | 69.5M | 49.7M | 58.4M | 150.6M | 156M | 391K | 6.5M | 3.4M | |
60.9M | 62.8M | 53.2M | 136.9M | 197.4M | 89.1M | 130.7M | 118.7M | 69M | 49.7M | 58.4M | 150.6M | 156M | 391K | 6.5M | |
-75.4M | -127.6M | -92.7M | -149.7M | -112.8M | -160.4M | -191M | -161.5M | -73.8M | -84.5M | -95.4M | -54.3M | -30.3M | -15.6M | -8.9M |
SEC Filings
KPTI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 28, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
S-3 S-3 N/A | May 04, 2026 | May 04, 2026 | ||
S-3 S-3 N/A | May 04, 2026 | May 04, 2026 | ||
DEF 14A DEF 14A 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 03, 2026 | February 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 18, 2026 | 2026 |
Related Guides
Continue your KPTI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.